Tharimmune receives Nasdaq noncompliance notice for board independence; plans cure at Jan 30 meeting

Canton Strategic Holdings, Inc.

Nasdaq notified Tharimmune on Jan 9, 2026 of noncompliance with Listing Rule 5605 (majority independent directors) following resignations of Nancy Davis and Sanam Parikh effective Nov 6, 2025.
Cure period ends on earlier of next annual shareholders' meeting or Nov 6, 2026; if annual meeting before May 5, 2026, then May 5, 2026.
Company will seek shareholder approval at a special meeting on Jan 30, 2026 to elect two additional independent directors to the Board.
After the special meeting, the Company expects a majority of its Board to be independent, regaining compliance.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.